Also found in: Medical.
CALGBCancer and Leukemia Group B
References in periodicals archive ?
Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202).
CALGB 100104 was a phase III, controlled, double-blind, multi-centre study of 460 patients with newly diagnosed multiple myeloma undergoing ASCT who were randomised to receive continuous daily treatment with Revlimid or placebo until relapse or intolerance.
Abbreviations AML -acute myeloid leukemia CALGB -Cancer and Leukemia Group B HDAC -high dose cytosine-arabinoside FAB -French-American-British CR -complete remission NPM -nucelophosmin M3 -acute promyelocit FLT3 -FMS-like tyrosine kinase 3
The impact of physical activity on patients with stage III colon cancer: Findings from Intergroup trial CALGB 89803.
The physicians participate in NCI-sponsored clinical research with SWOG, ECOG, CALGB, CTSU, University of Chicago, and MD Anderson Cancer Center, and actively collaborate with others in the community in providing multidisciplinary quality cancer care at Memorial Medical Center and St.
A randomized comparison of fludarabine and chlorambucil for patients with previously untreated chronic lymphocytic leukemia: a CALGB, SWOG, CTG/NCI-C and ECOG Intergroup Study.
Arm/hand swelling and perceived functioning among breast cancer survivors 12 years post-diagnosis: CALGB 79804.
Prognostic significance of reverse transcriptase polymerase chain reaction for prostate-specific antigen in metastatic prostate cancer: a nested study within CALGB 9583.
Measuring Disease-Free Survival and Cancer Relapse Using Medicare Claims from CALGB Breast Cancer Trial Participants (Companion to 9344).
Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from CALGB 8461.
The practice is affiliated with national Clinical Study protocol groups, CALGB, (Cancer and Leukemia Group B), and NSABP (National Surgical Adjuvant Breast and Bowel Project), offering patients the opportunity of national clinical studies, through The Vermont Regional Cancer Center.
Treatment was initiated according to CALGB protocol # 9621.